Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BE CONNECTED: Bimekizumab in Adolescent Plaque Psoriasis
NCT04718896Phase 2Completed
- Sponsor
- UCB
- Start
- Apr 2021
- Primary completion
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of bimekizumab in plaque psoriasis (2 arms), sponsored by UCB. Primary endpoint: Plasma Concentration of Bimekizumab at 140 weeks. Started Apr 2021; status: completed.
02
Drugs
bimekizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04718896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04718896.